• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA clears Zimmer Biomet’s Rosa Hip personalized robotic system

FDA clears Zimmer Biomet’s Rosa Hip personalized robotic system

August 18, 2021 By Danielle Kirsh

Zimmer Biomet logoZimmer Biomet (NYSE:ZBH) today announced that it received FDA 510(k) clearance for its Rosa Hip system for robotically-assisted surgery.

Warsaw, Ind.-based Zimmer Biomet designed the Rosa Hip personalized robotic system for direct anterior total hip replacement. It is the company’s fourth robotic system and adds to its Rosa robotic portfolio of orthopedic devices, which includes Rosa Knee, Rosa Partial Knee and Rosa One.

“We’re excited to announce the FDA clearance of Rosa Hip, and to now offer one of the most comprehensive orthopedic robotic solutions through a single, multiple application platforms,” chief operating officer Ivan Tornos said in a news release. “As an integrated component of our ZBEdge Connected Intelligence Suite, Rosa Hip advances our vision to translate pre-, intra-and post-operative data into actionable clinical insights to inform personalized care decisions.”

Rosa Hip is designed to assist direct anterior surgeons with preparation, positioning and component impaction while also intraoperatively quantifying cup orientation, leg length and offset.

Zimmer Biomet’s Rosa Hip system is compatible with a number of implant systems, including the Avenir Complete hip system. It uses fluoroscopy and provides robotic assistance to guide accurate acetabular component orientation and intra-operative assessment of leg length and offset.

“Rosa Hip will allow surgeons to retain complete control over case planning and execution while providing real-time data and visualization tools,” Atul Kamath, director for the Center for Hip Preservation at the Cleveland Clinic, said. “Even surgeons who are new to robotic-assisted surgery can easily tailor Rosa Hip to adapt to their own workflow. The robotic platform provides support during component positioning, cup impaction and other critical steps of an anterior approach total hip replacement. By reducing the intra-operative variability and inconsistency, this new technology has the potential to give surgeons and their patients greater confidence in seeking value in contemporary total hip replacement.”

Surgeons can use the company’s pre-operative planner One Planner Hip with the Rosa Hip system. One Planner has a spinopelvic mobility assessment tool for both a sitting and standing lateral X-ray and an auto-plan function that allows surgeons to create a pre-operative plan within five minutes.

Filed Under: 510(k), Food & Drug Administration (FDA), Orthopedics Tagged With: Zimmer Biomet

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy